CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy – Pharmacy Today, American Pharmacists Association, pharmacist.com
|
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Pharmacy Today, American Pharmacists Association, pharmacist.com NIH and Stanford University researchers designed a Phase I study to evaluate a new treatment for relapsed and/or refractory pre-B cell acute lymphoblastic leukemia (B-ALL). Current practice relies on the use of chimeric antigen receptor (CAR) T cells … |
